Discovery of Aryl Formyl Piperidine Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase Inhibitors
- 11 June 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (11), 5783-5796
- https://doi.org/10.1021/acs.jmedchem.9b02137
Abstract
Most of the current monoacylglycerol lipase (MAGL) inhibitors function by an irreversible mechanism of action, causing a series of side effects. Herein, starting from irreversible inhibitors, 25 compounds were synthesized and evaluated in vitro for MAGL inhibition, among which, compound 36 showed the most potent inhibitory activity (IC50 = 15 nM). Crucially, docking studies demonstrated that the m-chlorine-substituted aniline fragment occupied a hydrophobic subpocket enclosed by side chains of Val191, Tyr194, Val270, and Lys273, which creatively identify a new key anchoring point for the development of new MAGL inhibitors. Furthermore, in vivo evaluation innovatively revealed that this reversible inhibitor 36 significantly ameliorated depressive-like behaviors induced by reserpine. To the best of our knowledge, this is the first time that reversible inhibitors of MAGL were developed to support MAGL as a potential therapeutic target for depression.Funding Information
- China Pharmaceutical University (CPU2018PZQ07)
- Natural Science Foundation of Jiangsu Province (BK20191318)
This publication has 28 references indexed in Scilit:
- Modulating the endocannabinoid system in human health and disease – successes and failuresThe FEBS Journal, 2013
- The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2‐arachidonoylglycerol signalling through cannabinoid receptorsActa Physiologica, 2011
- The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptorsNature Neuroscience, 2010
- The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitationPharmacological Research, 2009
- Emerging strategies for exploiting cannabinoid receptor agonists as medicinesBritish Journal of Pharmacology, 2009
- A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-ArachidonoylglycerolCell Chemical Biology, 2007
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- Research and treatment approaches to depressionNature Reviews Neuroscience, 2001
- Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amidesNature, 1996
- Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonistBiochemical Pharmacology, 1993